Education
Krammer studied medicine at the University of Freiburg (Germany), in Street.Louis (United States of America) and in Lausanne (Switzerland) and graduated in 1971.
immunologist directors of The National Center
Krammer studied medicine at the University of Freiburg (Germany), in Street.Louis (United States of America) and in Lausanne (Switzerland) and graduated in 1971.
Peter H. Krammer is well known for his research and findings in apoptosis. He and his lab members discovered the CD95 receptor (also known as Fas and Army Post Office-1) and many other molecules involved in signaling through the CD95 receptor. In 1976, he became an associate at the Institute for and Genetics at the German Cancer Research Center in Heidelberg.
Between 1981 and 1988, he was the acting head and since 1989, he is the head of the Division of Immunogenetics at the German Cancer Research Center.
In 2000, he was one of the founders of Apogenix, a spin-out from the German Cancer Research Center which is a clinical stage biopharmaceutical company developing novel therapeutics by targeting the modulation of apoptosis. Since 2010, he is also one of the directors of The National Center for Tumor Diseases (NCT).
Peter H. Krammer has more than 400 scientific publications. Selection of 1991 Kind Phillip Award for Leukemia Research.
German Academy of Sciences Leopoldina. Heidelberg Academy for Sciences and Humanities]
He was a member of the Basel Institute for Immunology in Switzerland between 1973 and 1975, and a member of Max Planck Institute for Immunobiology in Freiburg, Germany in 1976.